{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:10:51Z","timestamp":1785409851596,"version":"3.56.0"},"reference-count":52,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology of Japan","doi-asserted-by":"crossref","award":["25K10101"],"award-info":[{"award-number":["25K10101"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]},{"award":["25K10101"],"award-info":[{"award-number":["25K10101"]}],"id":[{"id":"https:\/\/ror.org\/048rj2z13","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Dry eye disease (DED) is a multifactorial ocular surface disorder characterized by tear film instability and decreased tear secretion, largely driven by chronic ocular surface inflammation. Although current therapies primarily target inflammation and tear film stabilization, their clinical efficacy is often limited by insufficient ocular surface retention. In this study, we explored a drug repositioning strategy for DED by developing a nanocrystalline formulation of troxipide (TRO), a gastric mucosal protective agent with cytoprotective properties. Methods and Results: A TRO nanosuspension (TRO-NPs) was successfully prepared by wet bead milling, yielding particles with a mean diameter of approximately 100 nm. Physicochemical characterization revealed that the crystalline structure, solubility, viscosity, pH, and osmolarity of the nanosuspension were comparable with those of the conventional TRO microsuspension (TRO-MPs). In contrast, the TRO-NPs exhibited markedly improved dispersion stability, maintaining particle suspension for at least 1 month after preparation. Repeated topical instillation of the TRO-NPs did not induce corneal toxicity or inflammation in rabbits, and resulted in significantly higher drug retention in the tear fluid than that observed for the TRO-MPs. Furthermore, in an N-acetylcysteine-induced rabbit dry eye model, repetitive instillation of the TRO-NPs significantly increased tear volume and mucin levels, leading to improved tear film stability. Conclusions: These findings demonstrate that nanosuspension-based formulations can enhance ocular surface retention and therapeutic efficacy of TRO. TRO-NPs therefore represent a promising nanomedicine-based repositioned therapy for the treatment of DED.<\/jats:p>","DOI":"10.3390\/pharmaceutics18060699","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T07:43:02Z","timestamp":1780904582000},"page":"699","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ocular Troxipide Nanosuspension Enhances Therapeutic Efficacy in an N-Acetylcysteine-Induced Dry Eye Model"],"prefix":"10.3390","volume":"18","author":[{"given":"Hiroko","family":"Otake","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka 577-8502, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka 577-8502, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2755-8341","authenticated-orcid":false,"given":"Fumihiko","family":"Ogata","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka 577-8502, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-1944","authenticated-orcid":false,"given":"Yosuke","family":"Nakazawa","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Doshisha Woman\u2019s College of Liberal Arts, 97-1, Minamihokotate, Kodo, Kyotanabe 610-0395, Kyoto, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Misra","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics and Pharmacy Technology, L. M. College of Pharmacy, Navrangpura, Ahmedabad 380009, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3690-2332","authenticated-orcid":false,"given":"Kazutaka","family":"Kanai","sequence":"additional","affiliation":[{"name":"Department of Small Animal Internal Medicine II, School of Veterinary Medicine, Kitasato University, 35-1 Higashi 23 Ban-Cho, Towada 034-8628, Aomori, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3129-2678","authenticated-orcid":false,"given":"Masanobu","family":"Tsubaki","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacotherapy, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, 1314-1 Shido, Sanuki 769-2193, Kagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9659-3204","authenticated-orcid":false,"given":"Naoki","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"University Startup Promotion Center, Research Promotion Headquarters, Fujita Health University, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake 470-1192, Aichi, Japan"},{"name":"Department of Pharmaceutical Engineering, Faculty of Engineering, Sanyo-Onoda City University, 1-1-1 Daigaku-dori, Sanyo-Onoda 756-0884, Yamaguchi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9412-0868","authenticated-orcid":false,"given":"Naohito","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka 577-8502, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1266-038X","authenticated-orcid":false,"given":"Noriaki","family":"Nagai","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy, Kindai University, 3-4-1 Kowakae, Higashi-Osaka 577-8502, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"96","DOI":"10.4140\/TCP.n.2016.96","article-title":"Treatment of dry eye disease","volume":"31","author":"Marshall","year":"2016","journal-title":"Consult. Pharm."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II Epidemiology Report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul. Surf."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Chan, C. (2015). The Epidemiology of Dry Eye Disease. Dry Eye: A Practical Approach, Springer.","DOI":"10.1007\/978-3-662-44106-0"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1167\/iovs.11-9094","article-title":"Assessment of vision-related quality of life in dry eye patients","volume":"53","author":"Li","year":"2012","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jtos.2015.11.002","article-title":"Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review","volume":"14","author":"McDonald","year":"2016","journal-title":"Ocul. Surf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1080\/13543784.2016.1249564","article-title":"Investigational drugs in dry eye disease","volume":"25","author":"Nebbioso","year":"2016","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"D1192","DOI":"10.2741\/Moniaux","article-title":"Structural organization and classification of the human mucin genes","volume":"6","author":"Moniaux","year":"2001","journal-title":"Front. Biosci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S1542-0124(12)70149-0","article-title":"Character of ocular surface mucins and their alteration in dry eye disease","volume":"2","author":"Gipson","year":"2004","journal-title":"Ocul. Surf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0074-7696(03)31001-0","article-title":"Role of mucins in the function of the corneal and conjunctival epithelia","volume":"231","author":"Gipson","year":"2003","journal-title":"Int. Rev. Cytol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0014-4835(71)80028-3","article-title":"Wettability and wetting of the corneal epithelium","volume":"11","author":"Holly","year":"1971","journal-title":"Exp. Eye Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0039-6257(77)90087-X","article-title":"Tear physiology and dry eyes","volume":"22","author":"Holly","year":"1977","journal-title":"Surv. Ophthalmol."},{"key":"ref_12","first-page":"1684","article-title":"Expression of secretory mucin genes by human conjunctival epithelia","volume":"37","author":"Inatomi","year":"1996","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_13","first-page":"218","article-title":"Characteristics of a glycoprotein in the ocular surface glycocalyx","volume":"33","author":"Gipson","year":"1992","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00165940","article-title":"Morphological changes in ocular surface in dry eyes and other disorders by impression cytology","volume":"230","author":"Rivas","year":"1992","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_15","first-page":"2602","article-title":"Alteration of mucin in human conjunctival epithelia in dry eye","volume":"39","author":"Danjo","year":"1998","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1089\/adt.2015.29009.hmedrrr","article-title":"Sources and targets for drug repurposing: Landscaping transitions in therapeutic space","volume":"13","author":"Mucke","year":"2015","journal-title":"Assay Drug Dev. Technol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"758397","DOI":"10.1155\/2010\/758397","article-title":"Troxipide in the management of gastritis: A randomized comparative trial in general practice","volume":"2010","author":"Dewan","year":"2010","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.3109\/03639045.2014.956113","article-title":"Preparation and pharmacokinetics study on gastro-floating sustained-release tablets of troxipide","volume":"41","author":"Gao","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1023\/A:1005656916830","article-title":"Diclofenac-induced gastric mucosal fluorescence in rats","volume":"46","author":"Matsui","year":"2001","journal-title":"Dig. Dis. Sci."},{"key":"ref_20","first-page":"757","article-title":"Effects of troxipide on the prednisolone-induced aggravation of gastric mucosal lesions occurred by HC1 in rats","volume":"33","author":"Inoue","year":"2005","journal-title":"Jpn. Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1081\/DDC-120003445","article-title":"Ocular preparations: The formulation approach","volume":"28","author":"Kaur","year":"2002","journal-title":"Drug Dev. Ind. Pharm."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1089\/jop.2012.0200","article-title":"Novel strategies for anterior segment ocular drug delivery","volume":"29","author":"Cholkar","year":"2013","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2174\/1381612822666151216145900","article-title":"Ocular drug delivery\u2014New strategies for targeting anterior and posterior segments of the eye","volume":"22","author":"Fangueiro","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"114582","DOI":"10.1016\/j.addr.2022.114582","article-title":"Novel drug delivery systems for the management of dry eye","volume":"191","author":"Nagai","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"103738","DOI":"10.1016\/j.jpet.2025.103738","article-title":"Recent advances and future challenges in nanosystems for ocular drug delivery","volume":"392","author":"Shahror","year":"2025","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3892\/br.2021.1418","article-title":"Nanotechnology and its use in imaging and drug delivery (Review)","volume":"14","author":"Sim","year":"2021","journal-title":"Biomed. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Altammar, K.A. (2023). A review on nanoparticles: Characteristics, synthesis, applications, and challenges. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1155622"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Afzal, O., Altamimi, A.S.A., Nadeem, M.S., Alzarea, S.I., Almalki, W.H., Tariq, A., Mubeen, B., Murtaza, B.N., Iftikhar, S., and Riaz, N. (2022). Nanoparticles in Drug Delivery: From History to Therapeutic Applications. Nanomaterials, 12.","DOI":"10.3390\/nano12244494"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/nmat3776","article-title":"Stimuli-responsive nanocarriers for drug delivery","volume":"12","author":"Mura","year":"2013","journal-title":"Nat. Mater."},{"key":"ref_30","unstructured":"Mozafari, M. (2020). Nanoparticles for mucosal vaccine delivery. Nanoengineered Biomaterials for Advanced Drug Delivery, Elsevier."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1177\/0884533615609899","article-title":"Gut Microbiome: What We Do and Don\u2019t Know","volume":"30","author":"Cresci","year":"2015","journal-title":"Nutr. Clin. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.addr.2005.07.005","article-title":"The use of mucoadhesive polymers in ocular drug delivery","volume":"57","author":"Ludwig","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"491","DOI":"10.31083\/ph.2011.0358","article-title":"Development of a novel ophthalmic ciclosporin A-loaded nanosuspension using top-down media milling methods","volume":"66","author":"Kim","year":"2011","journal-title":"Die Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ejps.2013.07.002","article-title":"Developing an in situ nanosuspension: A novel approach towards the efficient administration of poorly soluble drugs at the anterior eye","volume":"50","author":"Luschmann","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.exer.2016.07.003","article-title":"Size effect of rebamipide ophthalmic nanodispersions on its therapeutic efficacy for corneal wound healing","volume":"151","author":"Nagai","year":"2016","journal-title":"Exp. Eye Res."},{"key":"ref_36","first-page":"283","article-title":"Preparation and evaluation of vitamin A nanosuspension as a novel ocular drug delivery","volume":"2","author":"Akhgari","year":"2015","journal-title":"Nanomed. J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ajo.2008.08.015","article-title":"A Comparison of Vitamin A and Cyclosporine A 0.05% Eye Drops for Treatment of Dry Eye Syndrome","volume":"147","author":"Kim","year":"2009","journal-title":"Am. J. Ophthalmol."},{"key":"ref_38","first-page":"721","article-title":"The in vitro reduction in viscosity of human tracheobronchial secretions by acetylcysteine","volume":"90","author":"Sheffner","year":"1964","journal-title":"Am. Rev. Respir. Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/978-1-4615-5359-5_36","article-title":"Mucous contribution to rat tear-film thickness measured with a microelectrode technique","volume":"438","author":"Anderton","year":"1998","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_40","first-page":"2958","article-title":"Effects of acetylcysteine on rabbit conjunctival and corneal surfaces","volume":"32","author":"Thermes","year":"1991","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0014-5793(00)01464-2","article-title":"N-Acetylcysteine suppresses TNF-induced NF-\u03baB activation through inhibition of I\u03baB kinases","volume":"472","author":"Oka","year":"2000","journal-title":"FEBS Lett."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"33018","DOI":"10.1074\/jbc.271.51.33018","article-title":"Suppression of nerve growth factor-induced neuronal differentiation of PC12 cells. N-acetylcysteine uncouples the signal transduction from ras to the mitogen-activated protein kinase cascade","volume":"271","author":"Kamata","year":"1996","journal-title":"J. Bio. Chem."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1046\/j.1432-1327.2000.01194.x","article-title":"Epidermal growth factor receptor is modulated by redox through multiple mechanisms. Effects of reductants and H2O2","volume":"267","author":"Kamata","year":"2000","journal-title":"Eur. J. Biochem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.tox.2014.02.012","article-title":"A nanoparticle formulation reduces the corneal toxicity of indomethacin eye drops and enhances its corneal permeability","volume":"319","author":"Nagai","year":"2014","journal-title":"Toxicology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2147\/IJN.S196681","article-title":"Energy-dependent endocytosis is responsible for drug transcorneal penetration following the instillation of ophthalmic formulations containing indomethacin nanoparticles","volume":"14","author":"Nagai","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Nagai, N., Ishii, M., Seiriki, R., Ogata, F., Otake, H., Nakazawa, Y., Okamoto, N., Kanai, K., and Kawasaki, N. (2020). Novel sustained-release drug delivery system for dry eye therapy by rebamipide nanoparticles. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020155"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Minami, M., Otake, H., Nakazawa, Y., Okamoto, N., Yamomoto, N., Sasaki, H., and Nagai, N. (2021). Balance of Drug Residence and Diffusion in Lacrimal Fluid Determine Ocular Bioavailability in In Situ Gels Incorporating Tranilast Nanoparticles. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13091425"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Nagai, N., Minami, M., Deguchi, S., Otake, H., Sasaki, H., and Yamamoto, N. (2020). An in situ Gelling System based on Methylcellulose and Tranilast Solid Nanoparticles Enhances Ocular Residence Time and Drug Absorption into the Cornea and Conjunctiva. Front. Bioeng. Biotechnol., 8.","DOI":"10.3389\/fbioe.2020.00764"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Nagai, N., Isaka, T., Deguchi, S., Minami, M., Yamaguchi, M., Otake, H., Okamoto, N., and Nakazawa, Y. (2020). In Situ Gelling Systems Using Pluronic F127 Enhance Corneal Permeability of Indomethacin Nanocrystals. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21197083"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.2147\/DDDT.S469445","article-title":"Copolymerized Polymers Based on Cyclodextrins and Cationic Groups Enhance Therapeutic Effect of Rebamipide in the N-acetylcysteine-treated Dry Eye Model","volume":"18","author":"Otake","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s40199-018-00235-2","article-title":"Formation of nanosuspensions in bottom-up approach: Theories and optimization","volume":"27","author":"Tehrani","year":"2019","journal-title":"DARU J. Pharm. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/nrd1494","article-title":"Nanosuspensions in drug delivery","volume":"3","author":"Rabinow","year":"2004","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/6\/699\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:16:41Z","timestamp":1781324201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/6\/699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,6]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["pharmaceutics18060699"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18060699","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,6]]}}}